임상 한눈에 보기

• 7건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 6건 · 완료/종료 0건
• Phase: Phase 1, Phase 2 · Phase 2
• Status: Available · Recruiting · Not yet recruiting
• 주요 endpoint: Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapy · Number of participants with DLTs for ubamatamab with cemiplimab · Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for ubamatamab monotherapy · Number of participants with TEAEs (including imAEs) for ubamatamab with cemiplimab · Number of participants with serious adverse events (SAEs) for ubamatamab monotherapy
• 등록 대상자(표본 합산): 약 2,105명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.